Impact of age on genetics and treatment efficacy in follicular lymphoma

被引：12
作者：
Alig, Stefan [1 ]
Jurinovic, Vindi [1 ,2 ]
Pastore, Alessandro [3 ]
Bararia, Deepak [1 ]
Haebe, Sarah [1 ]
Hellmuth, Johannes C. [1 ,4 ]
Kridel, Robert [5 ]
Gascoyne, Randy [6 ,7 ]
Schmidt, Christian [1 ]
Zoellner, Anna-Katharina [1 ]
Buske, Christian [8 ]
Dreyling, Martin [1 ]
Unterhalt, Michael [1 ]
Hiddemann, Wolfgang [1 ,9 ,10 ]
Hoster, Eva [1 ,2 ]
Weigert, Oliver [1 ,9 ,10 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany
[2] Ludwig Maximilians Univ Munchen, Inst Med Informat Biometry & Epidemiol, Munich, Germany
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Weill Cornell Med, Dept Med, Div Hematol & Med Oncol, New York, NY USA
[5] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[6] BC Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada
[7] BC Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC, Canada
[8] Univ Hosp Ulm, Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany
[9] German Canc Consortium DKTK, Munich, Germany
[10] German Canc Res Ctr, Heidelberg, Germany
来源：
HAEMATOLOGICA | 2018年 / 103卷 / 08期
关键词：
1ST-LINE TREATMENT; DISEASE CHARACTERISTICS; TREATMENT PATTERNS; RITUXIMAB; MUTATIONS; INDOLENT; OUTCOMES; TRIAL; CHOP;
D O I：
10.3324/haematol.2018.187773
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E364 / E367
页数：4
相关论文
共 15 条
  • [1] Reversal of Low Donor Chimerism Following Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion
    Bar, Merav
    Flowers, Mary
    Storer, Barry E.
    Chauncey, Thomas R.
    Pulsipher, Michael A.
    Thakar, Monica S.
    Bethge, Wolfgang
    Storb, Rainer F.
    Maloney, David G.
    Sandmaier, Brenda M.
    [J]. BLOOD, 2016, 128 (22)
  • [2] Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study
    Casulo, C.
    Day, B.
    Dawson, K. L.
    Zhou, X.
    Flowers, C. R.
    Farber, C. M.
    Hainsworth, J. D.
    Cerhan, J. R.
    Link, B. K.
    Zelenetz, A. D.
    Friedberg, J. W.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (11) : 2311 - 2317
  • [3] Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
    Federico, Massimo
    Bellei, Monica
    Marcheselli, Luigi
    Luminari, Stefano
    Lopez-Guillermo, Armando
    Vitolo, Umberto
    Pro, Barbara
    Pileri, Stefano
    Pulsoni, Alessandro
    Soubeyran, Pierre
    Cortelazzo, Sergio
    Martinelli, Giovanni
    Martelli, Maurizio
    Rigacci, Luigi
    Arcaini, Luca
    Di Raimondo, Francesco
    Merli, Francesco
    Sabattini, Elena
    McLaughlin, Peter
    Solal-Celigny, Philippe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4555 - 4562
  • [4] Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
    Flinn, Ian W.
    van der Jagt, Richard
    Kahl, Brad S.
    Wood, Peter
    Hawkins, Tim E.
    MacDonald, David
    Hertzberg, Mark
    Kwan, Yiu-Lam
    Simpson, David
    Craig, Michael
    Kolibaba, Kathryn
    Issa, Samar
    Clementi, Regina
    Hallman, Doreen M.
    Munteanu, Mihaela
    Chen, Ling
    Burke, John M.
    [J]. BLOOD, 2014, 123 (19) : 2944 - 2952
  • [5] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    Hiddemann, W
    Kneba, M
    Dreyling, M
    Schmitz, N
    Lengfelder, E
    Schmits, R
    Reiser, M
    Metzner, B
    Harder, H
    Hegewisch-Becker, S
    Fischer, T
    Kropff, M
    Reis, HE
    Freund, M
    Wörmann, B
    Fuchs, R
    Planker, M
    Schimke, J
    Eimermacher, H
    Trümper, L
    Aldaoud, A
    Parwaresch, R
    Unterhalt, M
    [J]. BLOOD, 2005, 106 (12) : 3725 - 3732
  • [6] Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
    Marcus, R.
    Davies, A.
    Ando, K.
    Klapper, W.
    Opat, S.
    Owen, C.
    Phillips, E.
    Sangha, R.
    Schlag, R.
    Seymour, J. F.
    Townsend, W.
    Trneny, M.
    Wenger, M.
    Fingerle-Rowson, G.
    Rufibach, K.
    Moore, T.
    Herold, M.
    Hiddemann, W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (14) : 1331 - 1344
  • [7] Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy.
    Murawski, Niels
    Miriam, Josif
    Altmann, Bettina
    Ziepert, Marita
    Haenel, Mathias
    Viardot, Andreas
    Neubauer, Andreas
    Held, Gerhard
    Truemper, Lorenz
    Schmidt, Christian
    Kanz, Lothar
    Hallek, Michael
    Schmitz, Norbert
    Heintges, Tobias
    Koelbel, Christian
    Poeschel, Viola
    Pfreundschuh, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States
    Nabhan, Chadi
    Byrtek, Michelle
    Rai, Ashish
    Dawson, Keith
    Zhou, Xiaolei
    Link, Brian K.
    Friedberg, Jonathan W.
    Zelenetz, Andrew D.
    Maurer, Matthew J.
    Cerhan, James R.
    Flowers, Christopher R.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (01) : 85 - 95
  • [9] Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
    Pastore, Alessandro
    Jurinovic, Vindi
    Kridel, Robert
    Hoster, Eva
    Staiger, Annette M.
    Szczepanowski, Monika
    Pott, Christiane
    Kopp, Nadja
    Murakami, Mark
    Horn, Heike
    Leich, Ellen
    Moccia, Alden A.
    Mottok, Anja
    Sunkavalli, Ashwini
    Van Hummelen, Paul
    Ducar, Matthew
    Ennishi, Daisuke
    Shulha, Hennady P.
    Hother, Christoffer
    Connors, Joseph M.
    Sehn, Laurie H.
    Dreyling, Martin
    Neuberg, Donna
    Moeller, Peter
    Feller, Alfred C.
    Hansmann, Martin L.
    Stein, Harald
    Rosenwald, Andreas
    Ott, German
    Klapper, Wolfram
    Unterhalt, Michael
    Hiddemann, Wolfgang
    Gascoyne, Randy D.
    Weinstock, David M.
    Weigert, Oliver
    [J]. LANCET ONCOLOGY, 2015, 16 (09) : 1111 - 1122
  • [10] Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
    Rummel, Mathias J.
    Niederle, Norbert
    Maschmeyer, Georg
    Banat, G. Andre
    von Gruenhagen, Ulrich
    Losem, Christoph
    Kofahl-Krause, Dorothea
    Heil, Gerhard
    Welslau, Manfred
    Balser, Christina
    Kaiser, Ulrich
    Weidmann, Eckhart
    Duerk, Heinz
    Ballo, Harald
    Stauch, Martina
    Roller, Fritz
    Barth, Juergen
    Hoelzer, Dieter
    Hinke, Axel
    Brugger, Wolfram
    [J]. LANCET, 2013, 381 (9873) : 1203 - 1210
12